Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo
YO42137
Phase 3 small_molecule active
Quick answer
Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo for Unresectable Esophageal Squamous Cell Carcinoma is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active